This website uses cookies. By using this website, you agree to our Cookie Policy.
June 22, 2022
Cadwalader advised Mithril II LP on its successful effort, together with M28 Capital, Population Health Partners, Polaris Partners and Adimab LLC, to add three directors to the classified board of biopharmaceutical company Adagio Therapeutics, Inc. Following a months-long proxy contest, all three of Mithril’s nominees – Population Health Partners co-founders Clive A. Meanwell and Tamsin Berry and M28 Capital founder Marc Elia – were elected to the Adagio board at the company’s annual meeting of shareholders held on Wednesday, June 22. Mithril holds an approximately 10.2% stake in the company.
Founded in 2012 by Ajay Royan with Peter Thiel, Mithril is a family of long-term venture capital funds that provides capital to leading growth companies by partnering with teams who use technology to build transformative and durable business, often in industries long overdue for change.
Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, including COVID-19 and influenza.
The Cadwalader team was led by Corporate co-chair Richard Brand and partner Kiran Kadekar and included senior attorney Brad Smith and associates Niral Shah and Benjamin Hughes, as well as Litigation partners Ellen Holloman and Michael Petrella, senior attorney Joshua Arnold and associates Annika Conrad and Jaclyn Hall.
